Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(22):1643; doi:10.1093/jnci/96.22.1643-a
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

MEMO TO THE MEDIA

Press Release

Researchers Call for Studies on Role of BRCA1 Mutations in Chemotherapy Response

Sarah L. Zielinski

jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

Loss of BRCA1 function is associated with sensitivity to DNA-damaging chemotherapy and may also be associated with resistance to taxane-based chemotherapy. However, prospective clinical studies are needed to evaluate the role of BRCA1 in chemotherapy response, concludes a new review in the November 17 issue of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?